| Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria |
|
Expert Review of Clinical Pharmacology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Optimal timing of allogeneic hematopoietic stem cell transplant in MDS |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
|
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
| Novel therapeutic choices in immune aplastic anemia |
|
F1000Research |
Aplastic Anemia |
| Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
|
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
|
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Newly revised 2023 MDS response criteria |
|
Blood |
Myelodysplastic Syndromes (MDS) |
